CA2478889A1 — Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
Assigned to Taisho Pharmaceutical Co Ltd · Expires 2004-02-19 · 22y expired
What this patent protects
It is intended to provide 5-thio-.beta.-D-glucopyranoside compounds represented by the following general formula (i), which show an effect of inhibiting the SGLT2 activity, pharmaceutically acceptable salts thereof or hydrates of the same; and drugs (in particular, preventives or…
USPTO Abstract
It is intended to provide 5-thio-.beta.-D-glucopyranoside compounds represented by the following general formula (i), which show an effect of inhibiting the SGLT2 activity, pharmaceutically acceptable salts thereof or hydrates of the same; and drugs (in particular, preventives or remedies for diabetes, diseases relating to diabetes or diabetic complications) containin g the same as the active ingredient: (i)
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.